Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCNS Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $1.34 | $1.34 | $1.34 |
| Q2 2024 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2024 | 1 | -$0.12 | -$0.12 | -$0.12 |
CNS Pharmaceuticals, Inc. Earnings Date And Information
CNS Pharmaceuticals, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.25 earnings per share for the quarter, missing analysts' consensus estimates of $-0.1 by $0.15. The company had revenue of 0 for the quarter and had revenue of 0 for the year. CNS Pharmaceuticals, Inc. has generated $-251 earnings per share over the last year ($-250.19 diluted earnings per share) and currently has a price-to-earnings ratio of -0.14. CNS Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 7th, 2025 based on prior year's report dates.
CNS Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.10 | -$0.25 | -0.15 | $0 | $0 |
| 08/14/2024 | Q2 2024 | -$52.08 | $0 | $0 | ||
| 05/15/2024 | Q1 2024 | -$57.36 | $0 | |||
| 04/01/2024 | Q4 2023 | -$95.00 | -$86.99 | 8.01 | $6,362 | |
| 11/14/2023 | Q3 2023 | -$86.50 | -$54.14 | 32.36 | $0 | |
| 08/14/2023 | Q2 2023 | -$141.00 | -$51.86 | 89.14 | $0 | |
| 05/15/2023 | Q1 2023 | -$120.00 | -$129.35 | -9.35 | $0 | |
| 05/01/2023 | Q4 2022 | -$173.09 | $0 | |||
| 11/10/2022 | Q3 2022 | -$2.40 | -$131.52 | -129.12 | $0 | |
| 08/12/2022 | Q2 2022 | -$2.40 | -$137.15 | -134.75 | $0 | |
| 05/13/2022 | Q1 2022 | -$126.07 | $0 | |||
| 03/03/2022 | Q4 2021 | -$31.50 | -$191.40 | -159.9 | $0 | |
| 11/12/2021 | Q3 2021 | -$31.50 | -$211.91 | -180.41 | $0 | |
| 08/13/2021 | Q2 2021 | -$24.00 | -$238.35 | -214.35 | $0 | |
| 05/13/2021 | Q1 2021 | -$225.84 | $0 | |||
| 02/12/2021 | Q4 2020 | -$13.50 | -$273.17 | -259.67 | $0 | |
| 11/12/2020 | Q3 2020 | -$3.60 | -$201.11 | -197.51 | $0 | |
| 08/10/2020 | Q2 2020 | -$2.40 | -$247.38 | -244.98 | $0 | |
| 05/15/2020 | Q1 2020 | -$3.00 | -$179.48 | -176.48 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.90 | -$230.47 | -229.57 | $0 |
CNS Pharmaceuticals, Inc. Earnings: FAQ's
When is CNS Pharmaceuticals, Inc.'s earnings date?
CNS Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 7th, 2025 based off last year's report dates.
How can I listen to CNS Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for CNS Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read CNS Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for CNS Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much profit does CNS Pharmaceuticals, Inc. generate each year?
CNS Pharmaceuticals, Inc. (:CNSP) has a recorded net income of $0. CNS Pharmaceuticals, Inc. has generated $-251.35 earnings per share over the last four quarters.
What is CNS Pharmaceuticals, Inc.'s price-to-earnings ratio?
CNS Pharmaceuticals, Inc. (:CNSP) has a price-to-earnings ratio of -0.14 and price/earnings-to-growth ratio is -0.01.